The effects of bufetolol (27.8-138.9 mumol/l), bunitrolol (70.2-351.1 mumol/l), bupranolol (16.2-100 mumol/l), carteolol (60.7-607 mumol/l), D32 (17.3-100 mumol/l), penbutolol (1.5-29.4 mumol/l) and timolol (115.5 and 231.2 mumol/l) on action potentials were investigated in isolated guinea-pig papillary muscles. All these beta-adrenoceptor blocking agents of teritary butyl aminopropranol derivatives produced a concentration-dependent reduction of Vmax at driving rates of 1 Hz, 0.027 Hz and 4 Hz. The reduction was frequency-dependent but at all the rates penbutolol was highest in potency, as estimated by ED30 (0.027 Hz) and ED 50 values (1 and 4 Hz), followed by bupranolol, D-32, bufetolol and bunitrolol. These were followed in turn by timolol and carteolol in ED30 at 0.027 Hz and ED50 at 1 Hz, but by carteolol and timolol in ED50 at 4 Hz. Each log (1/ED) value is a linear function of log n-octanol/water partition coefficient (log P). The slope and intercept (the value at log P = 0) of the line of log (1/ED50) at 4 Hz are steeper and higher, respectively, than those of the lines at the other frequencies. The time course of recovery of Vmax during diastole was studied by assessing Vmax in premature responses at 0.027 Hz, being approximated by a single exponential function. The time constants of recovery (tau) and intercepts (Ao: the value extrapolated to the time of APD90 of the conditioning responses) at the level of ED50 and at 100 mumol/l of the drugs were thus estimated.(ABSTRACT TRUNCATED AT 250 WORDS)
Proc West Pharmacol Soc. 1981;24:221-4
[PMID:
7255453]
Naunyn Schmiedebergs Arch Pharmacol. 1980 Oct;314(1):67-82
[PMID:
6777703]
Eur J Pharmacol. 1974 Dec;29(2):223-5
[PMID:
4155366]
Arzneimittelforschung. 1980;30(3):420-7
[PMID:
6992788]
Naunyn Schmiedebergs Arch Pharmacol. 1979 Nov;309(2):179-90
[PMID:
522903]
J Physiol. 1974 Aug;240(3):703-24
[PMID:
4415790]
Jpn J Pharmacol. 1977 Apr;27(2):227-32
[PMID:
18629]
Arzneimittelforschung. 1972 Jun;22(6):1061-5
[PMID:
5068354]
Naunyn Schmiedebergs Arch Pharmacol. 1973;277(2):211-26
[PMID:
4145013]
Jpn J Pharmacol. 1976 Dec;26(6):639-47
[PMID:
15153]
Jpn J Pharmacol. 1977 Dec;27(6):865-80
[PMID:
609152]
Eur J Pharmacol. 1972 Mar;17(3):341-51
[PMID:
4401812]
Arch Int Pharmacodyn Ther. 1978 Feb;231(2):232-42
[PMID:
25633]
Am Heart J. 1975 Dec;90(6):795-803
[PMID:
903]
J Pharmacol Exp Ther. 1980 Nov;215(2):507-14
[PMID:
6108361]
Naunyn Schmiedebergs Arch Pharmacol. 1978 Oct;304(3):191-201
[PMID:
714177]
Experientia. 1972 Jul 15;28(7):822-3
[PMID:
4144587]
Circ Res. 1982 Mar;50(3):369-76
[PMID:
6277526]
Naunyn Schmiedebergs Arch Pharmacol. 1979 May;307(1):1-8
[PMID:
39258]
J Cardiovasc Pharmacol. 1979 Mar-Apr;1(2):205-17
[PMID:
94390]
Arch Int Pharmacodyn Ther. 1973 Sep;205(1):76-93
[PMID:
4148410]
Arzneimittelforschung. 1974 Sep;24(9):1275-7
[PMID:
4154764]
Arch Int Pharmacodyn Ther. 1973 Apr;202(2):263-9
[PMID:
4144372]
Biochim Biophys Acta. 1977 Nov 14;472(3-4):373-98
[PMID:
334262]
J Gen Physiol. 1977 Apr;69(4):497-515
[PMID:
300786]
Naunyn Schmiedebergs Arch Pharmacol. 1981 Nov;317(3):245-51
[PMID:
6119623]
Experientia. 1981 Feb 15;37(2):171-2
[PMID:
6113159]
J Mol Cell Cardiol. 1980 Nov;12(11):1273-86
[PMID:
6777501]
Experientia. 1972 Jul 15;28(7):813-4
[PMID:
4144585]
J Gen Physiol. 1981 Oct;78(4):383-411
[PMID:
6270235]
J Pharmacol Exp Ther. 1980 Nov;215(2):539-43
[PMID:
7441515]
Eur J Pharmacol. 1976 Feb;35(2):235-43
[PMID:
2481]
Arzneimittelforschung. 1980;30(3):427-32
[PMID:
6104494]
Arch Int Pharmacodyn Ther. 1974 Aug;210(2):306-20
[PMID:
4441196]
